Small molecules for the treatment of primary cancer and cancer metastasis

Abstract

Certain embodiments are directed to non-hydrolysable ATP analogs and adenosine receptor antagonists that inhibit migration and growth of cancer cells.

1 . A compound that is a chemical analog of non-hydrolysable adenosine ATP analog 5′-[γ-thio]triphosphate (ATPγS) with general formula of Formula: I 
       
         
           
           
               
               
           
         
         where R1 and R2 are independently selected from hydrogen, cyano, C1 to C3 alkyl, halo, or heteromethyl. 
       
     
     
         2 . The compound of  claim 1 , wherein R1 is selected from hydrogen, cyano, C1 to C3 alkyl, halo, or heteromethyl, and R2 is a hydrogen or halogen. 
     
     
         3 . The compound of  claim 2 , wherein R1 is a hydrogen, fluoro, methyl, cyano, or trifluoromethyl. 
     
     
         4 . The compound of  claim 1 , wherein R1 is cyano and R2 is hydrogen, R1 is hydrogen and R2 is hydrogen, R1 is trifluoromethyl and R2 is hydrogen, R1 methyl and R2 is hydrogen, and R1 is fluoro and R2 is fluoro. 
     
     
         5 . A method for treating a cancer patient comprising administering to the patient an effective amount of a one or more compounds of  claim 1 . 
     
     
         6 . The method of  claim 5 , wherein the cancer is breast cancer. 
     
     
         7 . The method of  claim 5 , wherein one or more compounds of  claim 1  are administered intravenously. 
     
     
         8 . The method of  claim 5 , wherein one or more compounds of  claim 1  are administered orally. 
     
     
         9 . A compound that is a chemical analog of adenosine receptor antagonist 8-Ethoxy-9-ethyl-9H-purin-6-amine with general formula of Formula II 
       
         
           
           
               
               
           
         
         where R3 is a heteromethyl, cycloalkyl, or tetrahydrofuran. 
       
     
     
         10 . The compound of  claim 9 , wherein R3 is difluoro methyl, cyclopropyl, cyclobutyl, or β-tetrahydrofuran. 
     
     
         11 . A method for treating a cancer patient comprising administering to the patient an effective amount of one or more compounds of  claim 9 .